EIGER BIOPHARMACEUTICALS, INC. — Revenue by Fiscal Year
4 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/a48f7794-c40f-4de2-80b1-d449207f640d/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2023 | $15.8M | 2023-01-01 – 2023-12-31 | evidence 0001628280-24-015297 |
| FY 2022 | $13.5M | 2022-01-01 – 2022-12-31 | evidence 0001305253-23-000005 |
| FY 2021 | $12.1M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-009697 |
| FY 2020 | $0 | 2020-01-01 – 2020-12-31 | evidence 0001305253-23-000005 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
EIGER BIOPHARMACEUTICALS, INC. — all facts · Net Income · Operating Income